153 related articles for article (PubMed ID: 8706046)
1. Melanoma and vitiligo: immunology's Grecian urn.
Berd D; Mastrangelo MJ; Lattime E; Sato T; Maguire HC
Cancer Immunol Immunother; 1996 Jun; 42(5):263-7. PubMed ID: 8706046
[No Abstract] [Full Text] [Related]
2. Kobner phenomena as a complication of immune therapy of neoplastic disease.
James B
Autoimmunity; 1991; 10(2):165. PubMed ID: 1782328
[No Abstract] [Full Text] [Related]
3. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
4. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
5. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
[TBL] [Abstract][Full Text] [Related]
6. Malignant melanoma and vitiligo: can radiotherapy shed light on the subject?
Abood A; Saleh DB; Watt DA
J Plast Reconstr Aesthet Surg; 2009 May; 62(5):e119-20. PubMed ID: 18938120
[No Abstract] [Full Text] [Related]
7. Autoimmune disorders and interleukin-2 therapy: a step toward 'unanswered questions'.
Wolkenstein P; Revuz J; Guillaume JC; Avril MF; Chosidow O
Arch Dermatol; 1995 May; 131(5):615-6. PubMed ID: 7794409
[No Abstract] [Full Text] [Related]
8. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
Boasberg PD; Hoon DS; Piro LD; Martin MA; Fujimoto A; Kristedja TS; Bhachu S; Ye X; Deck RR; O'Day SJ
J Invest Dermatol; 2006 Dec; 126(12):2658-63. PubMed ID: 16946711
[TBL] [Abstract][Full Text] [Related]
9. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
10. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects. I. Circulating antibodies for cultured melanoma cells.
Takei M; Mishima Y; Uda H
J Cutan Pathol; 1984 Apr; 11(2):107-13. PubMed ID: 6376558
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients.
Jacobs JF; Aarntzen EH; Sibelt LA; Blokx WA; Boullart AC; Gerritsen MJ; Hoogerbrugge PM; Figdor CG; Adema GJ; Punt CJ; de Vries IJ
Cancer Immunol Immunother; 2009 Jan; 58(1):145-51. PubMed ID: 18392619
[TBL] [Abstract][Full Text] [Related]
12. A central role for inducible heat-shock protein 70 in autoimmune vitiligo.
Mosenson JA; Eby JM; Hernandez C; Le Poole IC
Exp Dermatol; 2013 Sep; 22(9):566-9. PubMed ID: 23786523
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.
Lacour JP; Caldani C; Thyss A; Schneider M; Ortonne JP
Dermatology; 1992; 184(4):283-5. PubMed ID: 1498395
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients.
Scheibenbogen C; Hunstein W; Keilholz U
Eur J Cancer; 1994; 30A(8):1209-11. PubMed ID: 7654462
[No Abstract] [Full Text] [Related]
15. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
16. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
18. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
Quaglino P; Marenco F; Osella-Abate S; Cappello N; Ortoncelli M; Salomone B; Fierro MT; Savoia P; Bernengo MG
Ann Oncol; 2010 Feb; 21(2):409-414. PubMed ID: 19622589
[TBL] [Abstract][Full Text] [Related]
19. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo as a post-bone marrow transplantation complication.
Cathcart S; Morrell D
J Pediatr Hematol Oncol; 2007 Jul; 29(7):485-7. PubMed ID: 17609627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
